The promise of targeted therapies in cancer was first realized with the discovery of the fusion between BCR (breakpoint cluster region gene) and ABL1 (Abelson tyrosine-protein kinase 1) genes in chronic myelogenous leukemia (CML) patients. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.